BioMérieux Shares Hit Lowest Since 2019, RSI Drops to 17
The stock of the Lyon-based in vitro diagnostics specialist continues its downward spiral. In mid-afternoon on Wednesday, April 29, 2026, the stock fell by 0.43% to €69.50, after having touched €69.25 during the session, its lowest level since 2019. The company's market capitalization has now declined by 40% over the year.
A Seven-Year Low in Tight Trading Volumes
BioMérieux's stock recorded a new session low at €69.25, falling below the previous low of €69.30 set in 2019. The stock thus sinks below its technical support threshold identified at €70.95, a level whose breach paves the way to uncharted territory since pre-Covid times. Over the past seven days, the decline reached 23.29%, while the quarterly performance stands at -30.01%. This contrasts sharply with the 200-day moving average, which is at €107.43, more than 35% above the current price. Meanwhile, the CAC 40 only lost 0.18% in the session, to 8,089.30 points, highlighting the marked underperformance of the stock. Within the healthcare sector, European comparables also moved into negative territory (Sanofi down by 0.75% and UCB by 1.14%), but to a lesser extent compared to the drop of the Lyon-based group.
A Technical Configuration in Extreme Oversold
The indicators reflect a state of tension rarely seen on the stock. The 14-day RSI stands at 17, well below the usual oversold threshold of 30. This indicator, which measures the speed and magnitude of price changes, signals a statistically significant bearish excess. Concurrently, the price of €69.50 is trading below the lower Bollinger Band set at €77.18, confirming the abnormal deviation of the stock from its recent average. The upper band, at €101.04, illustrates the extent of the corridor traversed in a few weeks. The financial calendar offers few immediate catalysts: the next major deadline is set for July 28, 2026, with the publication of the half-year results. Until then, the stock will have to contend with a macroeconomic environment burdened by the surge in Brent crude above $114 a barrel and geopolitical tensions in the Middle East, weighing on all European indices.
